Fundraising Fox

Excelerate Health Ventures

Venture capitalActively deploying

Research Triangle Park · Seed–Series A · 30 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

EHV believes pharma tech represents the next evolution of healthcare software. The firm backs software and tech-enabled services that improve time to market and effectiveness in the pharmaceutical industry, particularly AI-powered solutions. It prioritizes capital-efficient B2B SaaS models with large markets, defensible competitive advantages through proprietary technology, data flywheels, or network effects. The firm's investor base includes pharma, provider, and payer executives who serve as both potential customers and acquirers for portfolio companies.

Source: firm website, verified Jul 21, 2026.

Stage
Seed–Series A
HQ
Research Triangle Park, US
Leads rounds
Leads
Instruments
Equity
Tracked investments
1

Team · 30 people

from the firm's website
Andrew Schwab· Managing Partner

Serial entrepreneur and investor with over 30 years of experience building and growing technology-focused startups, including multiple successful exits. Led the First Flight Venture Center where he mentored more than 30 healthtech companies on financing, operations, and M&A strategy.

B. Bobby Bahram· Managing Partner

Co-founder of Excelerate Health Ventures with 25 years of experience building and scaling healthcare software and tech-enabled service startups. Has held founding CEO, CFO, and COO positions and has directed multiple healthcare companies through significant corporate events.

Maulik Mehta· Managing Partner

Brings over 25 years of experience in life sciences, healthcare tech, and chemicals with expertise in global business development and M&A. Previously served as President and Chief Business Officer at TriNetX, VP of Corporate Development at Quintiles, and Director of Investment Analytics at NovaQuest.

Gary Abrahams· Venture Partner

Brings 30 years of sales, marketing, and product leadership experience across healthcare enterprise, mobile, clinical, and imaging software sectors. Serves as Managing Partner of EHV Fund I.

Laura Hilty· Venture Partner

Health technology operator turned venture investor with two decades of experience in digital health and clinical research. Brings deep expertise in pharma tech and platform M&A.

Max Kanevsky· Venture Partner

Former CTO at Certara and founder and CEO of Pinnacle 21, an industry-standard clinical trial data validation platform that was subsequently acquired by Certara.

Phillip Johnston· Venture Partner

HealthTech and PharmaTech executive who previously served as VP of Product at Certara, where he led the Certara Cloud platform supporting 15+ scientific applications.

Abhi Mehrotra· Digital Health Advisor

Clinical operational leader and entrepreneur with healthcare technology and operational expertise.

Adrienne Kirby· Digital Health Advisor

Health system executive with operational healthcare leadership experience.

Al Peters· Digital Pharma Advisor

Clinical research and CRO operations executive.

Andrew Bier· Digital Pharma Advisor

Biopharma clinical operations and commercial strategy expert with experience as a former Merck Oncology President and biopharma board director.

Bruce Boehm· Digital Health Advisor

Advisor to venture capital funds with expertise in digital health.

Cam Patterson· Digital Health Advisor

Nationally recognized healthcare IT leader and health system executive.

David Muntz· Digital Health Advisor

Healthcare technology and policy leader.

Dhiren Patel· Digital Pharma Advisor

Pharma services and clinical research specialist.

Don Holzworth· Digital Health Advisor

Serial entrepreneur and public health executive with investment experience in the healthcare sector.

Eric Yablonka· Digital Health Advisor

Healthcare CIO and technology operations expert.

Fred Goldwater· Digital Health Advisor

Payer and operational healthcare executive with investment experience.

Jai Parekh· Digital Health Advisor

Ophthalmologist and operational healthcare leader with clinical and business expertise.

Jeanne Hecht· Digital Pharma Advisor

Pharma commercialization and patient engagement leader.

Jill DeSimone· Digital Pharma Advisor

Biopharma business development and M&A advisor.

John Potthoff· Digital Pharma Advisor

CRO and clinical trials leader.

Mark Friedman· Digital Health Advisor

DSO investor and digital health expert.

Martin Gouldstone· Digital Pharma Advisor

Generative AI and digital innovation strategist.

Michael Loscalzo· Digital Health Advisor

Health system executive and healthcare investment banking specialist.

Selene Parekh· Digital Health Advisor

Ophthalmologist and operational healthcare leader with clinical and business expertise.

Seth Glickman· Digital Health Advisor

Payer and physician executive with experience in healthcare operations and investment, offering executive coaching services.

Shwen Gwee· Digital Pharma Advisor

Pharma services and clinical research innovator.

Sue Schade· Digital Health Advisor

Healthcare CIO and technology operations leader.

Tania Malik· Digital Health Advisor

Telemedicine and behavioral health entrepreneur with investment experience and legal background.

What they invest in

from 1 of 1 portfolio companies

AI & Machine Learning ×1Digital Health ×1Healthtech ×1

HQs:United States×2

Investments · 1 tracked

founders shown can be your intro path
BEKHealthbekhealth.com

BEKhealth provides AI-powered clinical intelligence software that extracts data from electronic health records to enable faster clinical trial recruitment and real-world evidence generation. The platform serves sponsors, contract research organizations (CROs), research site networks, and healthcare organizations seeking to identify eligible patients and leverage clinical data for research.

AI & Machine LearningDigital HealthHealthtech

Board seats · per SEC filings · 2

what is this? ⓘ
OrbitalRx, Inc.SEC filing

$2.5M raise · filed Oct 2025 · via Gary S. Abrahams

Geno.Me, Inc.SEC filing

$650K raise · filed May 2025 · via Laura Hilty

Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Frequently asked questions

What stage does Excelerate Health Ventures invest at?
Excelerate Health Ventures invests at the Seed, Series A stages.
What sectors does Excelerate Health Ventures focus on?
Excelerate Health Ventures focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, SaaS.
Where is Excelerate Health Ventures located?
Excelerate Health Ventures is headquartered in Research Triangle Park, US.
Does Excelerate Health Ventures lead rounds?
Yes, Excelerate Health Ventures leads investment rounds.

Similar investors

B Capital Group

B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.

DCVC (Data Collective)

DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.

GV (Google Ventures)

GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.

Hyderabad Angels

Hyderabad Angels is a collective of experienced entrepreneurs, industrialists, and family offices founded in 2010 that provides mentorship, capital, and network access to early-stage founders. The organization invests in seed and pre-seed companies across sector-agnostic technology, healthcare, consumer, and other emerging sectors.

$6.3K – $50K
Khosla Ventures

Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.

Featured in lists